1047P Lung-MAP S1800A: Exploratory analysis of prior immunotherapy outcomes on OS with ramucirumab plus pembrolizumab for NSCLC with PD on prior ICI

K Reckamp,M.W Redman,K Dragnev,L Villaruz,B Faller,T Al Baghdadi,S Hines,K Minichiello,D.R Gandara,K Kelly,R.S Herbst

doi:10.1016/j.annonc.2022.07.1173

1047P Lung-MAP S1800A: Exploratory analysis of prior immunotherapy outcomes on OS with ramucirumab plus pembrolizumab for NSCLC with PD on prior ICI

K Reckamp, M.W Redman + Show 9 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.1173

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2022
Citations: 1

Affiliation: Cedars-Sinai Medical Center, Fred Hutch Cancer Center, Dartmouth–Hitchcock Medical Center, UPMC Hillman Cancer Center, Heartland Cancer Research, Missouri Baptist Medical Center, Trinity Health, Novant Health, University of California, Davis, Yale University

#Prior Immune Checkpoint Inhibitor #Immune Checkpoint Inhibitor Therapy + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Resistance develops following treatment with immune checkpoint inhibitor (ICI) therapy for non-small cell lung cancer (NSCLC), even after initial stabilization or response. Vascular endothelial growth factor receptor (VEGFR) and ICI therapy has demonstrated benefit across solid tumor types. We showed improved overall survival (OS) with pembrolizumab and ramucirumab (P+R) compared to standard-of-care (SOC) following progression on prior platinum-based doublet and ICI in patients with advanced NSCLC (HR: 0.69, 1-sided p-value=0.05.

Full Text